![](https://cdn.koreabiomed.com/news/thumbnail/202409/25067_26102_334_v150.jpg)
Samsung Bioepis settles patent dispute with Alexion, readies US launch of Soliris biosimilar
Samsung Bioepis has reached a settlement with Alexion Pharmaceuticals, ending their patent dispute over the blockbuster drug Soliris (ingredient: eculizumab) in the U.S. This agreement clears the path for Samsung Bioepis to launch its biosimilar version, …